In:
Clinical & Translational Immunology, Wiley, Vol. 4, No. 4 ( 2015-04)
Abstract:
A vaccine developed against the deadliest form of leishmaniasis is protective in mice and provokes a robust human immune response. Two different species of the sandfly‐borne Leishmania parasite cause visceral leishmaniasis (VL), a potentially lethal disease that affects 200–400,000 people annually. The efficacy of existing drugs is dwindling, but researchers led by Rhea Coler at the Infectious Disease Research Institute in Seattle, USA, have devised a promising vaccine candidate based on two parasite proteins. The vaccine stimulated a potent immune response in mice, and this response protected against disease by both the parasite species associated with VL. The researchers subsequently vaccinated 36 healthy human volunteers, and showed that the candidate vaccine was safe and induced an immune response against the appropriate parasite proteins, clearing the way for early‐stage clinical trials.
Type of Medium:
Online Resource
ISSN:
2050-0068
,
2050-0068
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2694482-0
